- Home
- RCS vs ITOS Comparison
RCS vs ITOS Comparison
Compare RCS & ITOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RCS
- ITOS
- Stock Information
- Founded
- RCS 1994
- ITOS 2011
- Country
- RCS United States
- ITOS United States
- Employees
- RCS N/A
- ITOS N/A
- Industry
- RCS Investment Managers
- ITOS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RCS Finance
- ITOS Health Care
- Exchange
- RCS Nasdaq
- ITOS Nasdaq
- Market Cap
- RCS 292.8M
- ITOS 270.7M
- IPO Year
- RCS N/A
- ITOS 2020
- Fundamental
- Price
- RCS $6.37
- ITOS $6.89
- Analyst Decision
- RCS
- ITOS Strong Buy
- Analyst Count
- RCS 0
- ITOS 3
- Target Price
- RCS N/A
- ITOS $26.00
- AVG Volume (30 Days)
- RCS 141.1K
- ITOS 384.6K
- Earning Date
- RCS 01-01-0001
- ITOS 03-05-2025
- Dividend Yield
- RCS 10.12%
- ITOS N/A
- EPS Growth
- RCS N/A
- ITOS N/A
- EPS
- RCS N/A
- ITOS N/A
- Revenue
- RCS N/A
- ITOS $35,000,000.00
- Revenue This Year
- RCS N/A
- ITOS N/A
- Revenue Next Year
- RCS N/A
- ITOS $121.70
- P/E Ratio
- RCS N/A
- ITOS N/A
- Revenue Growth
- RCS N/A
- ITOS 177.89
- 52 Week Low
- RCS $4.51
- ITOS $6.67
- 52 Week High
- RCS $6.31
- ITOS $18.75
- Technical
- Relative Strength Index (RSI)
- RCS 47.88
- ITOS 42.10
- Support Level
- RCS $6.22
- ITOS $6.73
- Resistance Level
- RCS $6.32
- ITOS $7.65
- Average True Range (ATR)
- RCS 0.13
- ITOS 0.38
- MACD
- RCS 0.01
- ITOS -0.00
- Stochastic Oscillator
- RCS 45.83
- ITOS 21.94
About RCS PIMCO Strategic Income Fund Inc.
PIMCO Strategic Income Fund, Inc. operates as a closed-end management investment company. Its primary investment objective is to generate a level of income that is higher than that generated by high-quality, intermediate-term U.S. debt securities. The Fund also seeks capital appreciation to the extent consistent with this objective.
About ITOS iTeos Therapeutics Inc.
ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.